{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:10:02Z","timestamp":1741219802271,"version":"3.38.0"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/mjt.0b013e31820e828c","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T16:06:53Z","timestamp":1307117213000},"page":"300-314","source":"Crossref","is-referenced-by-count":5,"title":["Pulmonary Arterial Hypertension"],"prefix":"10.1097","volume":"19","author":[{"given":"Eric S.","family":"Papierniak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Lowenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Mubarak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210202","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":". Updated clinical classification of pulmonary hypertension.","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R2-10-20210202","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":". Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"R3-10-20210202","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":". Updated evidence-based treatment algorithm in pulmonary arterial hypertension.","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R5-10-20210202","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":". Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R6-10-20210202","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":". Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.","volume":"161","author":"Miyamoto","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R7-10-20210202","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1183\/09031936.01.17406470","article-title":". Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension.","volume":"17","author":"Paciocco","year":"2001","journal-title":"Eur Respir J"},{"key":"R8-10-20210202","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":". A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"R9-10-20210202","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","article-title":". Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"R10-10-20210202","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.129.5.1313","article-title":". Serum Nterminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.","volume":"129","author":"Fijalkowska","year":"2006","journal-title":"Chest"},{"key":"R11-10-20210202","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-108-3-425","article-title":"Pulmonary hypertension from chronic pulmonary thromboembolism.","volume":"108","author":"Rich","year":"1988","journal-title":"Ann Intern Med"},{"key":"R12-10-20210202","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.112.3.714","article-title":". The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.","volume":"112","author":"Frank","year":"1997","journal-title":"Chest"},{"key":"R13-10-20210202","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0735-1097(86)80277-7","article-title":"Regression in thromboembolic type of primary pulmonary hypertension during 2 12 years of antithrombotic therapy.","volume":"7","author":"Cohen","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R14-10-20210202","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"R15-10-20210202","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1378\/chest.114.3.787","article-title":". The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension.","volume":"114","author":"Rich","year":"1998","journal-title":"Chest"},{"key":"R16-10-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.CIR.67.1.155","article-title":". Captopril in primary pulmonary hypertension.","volume":"67","author":"Leier","year":"1983","journal-title":"Circulation"},{"key":"R17-10-20210202","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJM198206033062203","article-title":". Deleterious effects of hydralazine in patients with pulmonary hypertension.","volume":"306","author":"Packer","year":"1982","journal-title":"N Engl J Med"},{"key":"R18-10-20210202","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM198001103020201","article-title":"Oral hydralazine therapy for primary pulmonary hypertension.","volume":"302","author":"Rubin","year":"1980","journal-title":"N Engl J Med"},{"key":"R19-10-20210202","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9149(84)90265-0","article-title":". Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension.","volume":"54","author":"Fisher","year":"1984","journal-title":"Am J Cardiol"},{"key":"R20-10-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/HYPERTENSIONAHA.108.125468","article-title":". Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer.","volume":"54","author":"Yamazato","year":"2009","journal-title":"Hypertension"},{"key":"R21-10-20210202","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1164\/rccm.200811-1678OC","article-title":". Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.","volume":"179","author":"Ferreira","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-10-20210202","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":". Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"R23-10-20210202","first-page":"490","article-title":"Breuer H, et al..","volume":"15","author":"Hoeper","year":"1994","journal-title":"How effective is the treatment with high-dose nifedipine for primary pulmonary hypertension Semin Respir Crit Care Med"},{"key":"R24-10-20210202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.76.1.135","article-title":"High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.","volume":"76","author":"Rich","year":"1987","journal-title":"Circulation"},{"key":"R25-10-20210202","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/hrt.75.2.171","article-title":". Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension.","volume":"75","author":"Woodmansey","year":"1996","journal-title":"Heart"},{"key":"R26-10-20210202","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0735-1097(84)80048-0","article-title":"Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.","volume":"4","author":"Packer","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"R27-10-20210202","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.CIR.89.3.1203","article-title":". Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.","volume":"89","author":"Seo","year":"1994","journal-title":"Circulation"},{"key":"R28-10-20210202","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","article-title":". ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.","volume":"165","author":"Davie","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R29-10-20210202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","article-title":"The endothelin system in pulmonary arterial hypertension.","volume":"61","author":"Galie","year":"2004","journal-title":"Cardiovasc Res"},{"key":"R30-10-20210202","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1152\/jappl.1996.81.4.1510","article-title":"Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors.","volume":"81","author":"Dupuis","year":"1996","journal-title":"J Appl Physiol"},{"key":"R31-10-20210202","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1172\/JCI116338","article-title":". Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells.","volume":"91","author":"Hirata","year":"1993","journal-title":"J Clin Invest"},{"key":"R32-10-20210202","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.CIR.103.2.314","article-title":". Effectiveness of a nonselective ET(AB) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.","volume":"103","author":"Jasmin","year":"2001","journal-title":"Circulation"},{"key":"R33-10-20210202","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":". Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"R34-10-20210202","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2362.2006.01688.x","article-title":"Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.","volume":"36","author":"McLaughlin","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"R35-10-20210202","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","article-title":". Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur Heart J"},{"key":"R37-10-20210202","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":". Ambrisentan therapy for pulmonary arterial hypertension.","volume":"46","author":"Galie","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R38-10-20210202","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":". Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"R39-10-20210202","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":". Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"R41-10-20210202","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1074\/jbc.274.20.13729","article-title":"Cyclic GMP phosphodiesterase-5: target of sildenafil.","volume":"274","author":"Corbin","year":"1999","journal-title":"J Biol Chem"},{"key":"R42-10-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00395-004-0504-5","article-title":". Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells.","volume":"100","author":"Tantini","year":"2005","journal-title":"Basic Res Cardiol"},{"key":"R43-10-20210202","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":". Sildenafil citrate therapy for pulmonary arterial hypertension.","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"R44-10-20210202","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","article-title":". Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.","volume":"108","author":"Michelakis","year":"2003","journal-title":"Circulation"},{"key":"R45-10-20210202","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":". Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"R46-10-20210202","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":". Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"R47-10-20210202","first-page":"273","article-title":"The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.","volume":"6","author":"Falk","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"R48-10-20210202","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2009.07.015","article-title":"A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension.","volume":"104","author":"Mubarak","year":"2010","journal-title":"Respir Med"},{"key":"R49-10-20210202","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.biocel.2003.08.006","article-title":". Prostanoids and prostanoid receptors in signal transduction.","volume":"36","author":"Bos","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"R50-10-20210202","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pharmthera.2004.06.003","article-title":"Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation.","volume":"103","author":"Hata","year":"2004","journal-title":"Pharmacol Ther"},{"key":"R51-10-20210202","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1100\/tsw.2007.182","article-title":"Prostaglandin receptor signaling in disease.","volume":"7","author":"Matsuoka","year":"2007","journal-title":"Scientific World Journal"},{"key":"R52-10-20210202","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0090-6980(02)00055-2","article-title":"Function of prostanoid receptors: studies on knockout mice.","volume":"68-","author":"Kobayashi","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"R53-10-20210202","doi-asserted-by":"crossref","first-page":"11395","DOI":"10.1074\/jbc.M411189200","article-title":". Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1.","volume":"280","author":"Kobayashi","year":"2005","journal-title":"J Biol Chem"},{"key":"R54-10-20210202","first-page":"28","article-title":". Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis.","volume":"62","author":"Mutoh","year":"2002","journal-title":"Cancer Res"},{"key":"R55-10-20210202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.semarthrit.2006.03.005","article-title":"Prostaglandins in health and disease: an overview.","volume":"36","author":"Miller","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"R56-10-20210202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM198407263110401","article-title":". The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men.","volume":"311","author":"Hardy","year":"1984","journal-title":"N Engl J Med"},{"key":"R57-10-20210202","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0031-6997(25)06784-5","article-title":"International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.","volume":"46","author":"Coleman","year":"1994","journal-title":"Pharmacol Rev"},{"key":"R58-10-20210202","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions.","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol Rev"},{"key":"R59-10-20210202","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.129.4.1627","article-title":". Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE.","volume":"129","author":"Lewis","year":"1982","journal-title":"J Immunol"},{"key":"R60-10-20210202","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/sj.bjp.0704423","article-title":". Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.","volume":"134","author":"Walch","year":"2001","journal-title":"Br J Pharmacol"},{"key":"R61-10-20210202","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.bjp.0705645","article-title":". EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries.","volume":"141","author":"Davis","year":"2004","journal-title":"Br J Pharmacol"},{"key":"R62-10-20210202","doi-asserted-by":"crossref","first-page":"C1203","DOI":"10.1152\/ajpcell.1996.271.4.C1203","article-title":". Iloprost activates KCa channels of vascular smooth muscle cells: role of cAMP-dependent protein kinase.","volume":"271","author":"Schubert","year":"1996","journal-title":"Am J Physiol"},{"key":"R63-10-20210202","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(98)00549-4","article-title":". Evidence that Ca2-activated K channels play a major role in mediating the vascular effects of iloprost and cicaprost.","volume":"356","author":"Clapp","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"R64-10-20210202","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2004.01.003","article-title":". Prostacyclin and its analogues in the treatment of pulmonary hypertension.","volume":"102","author":"Olschewski","year":"2004","journal-title":"Pharmacol Ther"},{"key":"R65-10-20210202","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1471-0528.1981.tb01009.x","article-title":". Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding.","volume":"88","author":"Smith","year":"1981","journal-title":"Br J Obstet Gynaecol"},{"key":"R66-10-20210202","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1210\/endo-106-5-1599","article-title":"The effect of 17 beta-estradiol and progesterone on prostaglandin production by human endometrium maintained in organ culture.","volume":"106","author":"Abel","year":"1980","journal-title":"Endocrinology"},{"key":"R67-10-20210202","first-page":"H2197","article-title":". Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo.","volume":"271","author":"Lai","year":"1996","journal-title":"Am J Physiol"},{"key":"R68-10-20210202","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1388-1981(99)00164-X","article-title":". The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.","volume":"1483","author":"Abramovitz","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"R69-10-20210202","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0031-6997(25)06759-6","article-title":"Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.","volume":"30","author":"Moncada","year":"1978","journal-title":"Pharmacol Rev"},{"key":"R70-10-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.prostaglandins.2006.05.011","article-title":"Cardioprotective prostacyclin signaling in vascular smooth muscle.","volume":"82","author":"Fetalvero","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"R71-10-20210202","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1161\/hc4301.098058","article-title":". Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors.","volume":"104","author":"Xiao","year":"2001","journal-title":"Circulation"},{"key":"R72-10-20210202","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/41780","article-title":". Altered pain perception and inflammatory response in mice lacking prostacyclin receptor.","volume":"388","author":"Murata","year":"1997","journal-title":"Nature"},{"key":"R73-10-20210202","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00001756-200201210-00022","article-title":". Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation.","volume":"13","author":"Doi","year":"2002","journal-title":"Neuroreport"},{"key":"R74-10-20210202","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bjp.0702393","article-title":". Prostanoid receptors involved in the relaxation of human pulmonary vessels.","volume":"126","author":"Walch","year":"1999","journal-title":"Br J Pharmacol"},{"key":"R75-10-20210202","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":". Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"R76-10-20210202","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"R77-10-20210202","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":". Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"R78-10-20210202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.CIR.64.1.4","article-title":". Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3:5-cyclic monophosphate levels.","volume":"64","author":"Data","year":"1981","journal-title":"Circulation"},{"key":"R81-10-20210202","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":". Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N Engl J Med"},{"key":"R82-10-20210202","doi-asserted-by":"crossref","first-page":"32037","DOI":"10.1074\/jbc.M003873200","article-title":". Internalization and sequestration of the human prostacyclin receptor.","volume":"275","author":"Smyth","year":"2000","journal-title":"J Biol Chem"},{"key":"R83-10-20210202","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":". Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R84-10-20210202","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":". Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"R85-10-20210202","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.amjcard.2006.09.119","article-title":"Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.","volume":"99","author":"Ivy","year":"2007","journal-title":"Am J Cardiol"},{"key":"R86-10-20210202","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","article-title":". Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.","volume":"132","author":"Rubenfire","year":"2007","journal-title":"Chest"},{"key":"R87-10-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0b013e31802b3184","article-title":". Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.","volume":"49","author":"Sitbon","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"R88-10-20210202","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":". Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"R89-10-20210202","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":". Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R90-10-20210202","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1378\/chest.07-2111","article-title":". Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.","volume":"134","author":"Benza","year":"2008","journal-title":"Chest"},{"key":"R91-10-20210202","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.178.3.1628","article-title":". Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities.","volume":"178","author":"Aronoff","year":"2007","journal-title":"J Immunol"},{"key":"R92-10-20210202","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1165\/ajrcmb.26.2.4695","article-title":". Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.","volume":"26","author":"Clapp","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R93-10-20210202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":". Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers.","volume":"44","author":"Laliberte","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"R96-10-20210202","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":". Inhaled iloprost for severe pulmonary hypertension.","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"R98-10-20210202","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":". Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R99-10-20210202","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":". Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"R100-10-20210202","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":". Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann Intern Med"},{"key":"R101-10-20210202","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.200710-1519OC","article-title":". Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension.","volume":"178","author":"Lai","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R102-10-20210202","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.124.4.1294","article-title":". Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.","volume":"124","author":"Olschewski","year":"2003","journal-title":"Chest"},{"key":"R103-10-20210202","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/jam.2006.19.353","article-title":". Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development.","volume":"19","author":"Schermuly","year":"2006","journal-title":"J Aerosol Med"},{"key":"R104-10-20210202","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":". Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.","volume":"39","author":"Galie","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R105-10-20210202","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":". Beraprost therapy for pulmonary arterial hypertension.","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R106-10-20210202","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1378\/chest.126.1.90","article-title":". Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension.","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"R107-10-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0922-4106(92)90075-7","article-title":"Eicosanoids modulate CR1- and Fc-dependent bacterial phagocytosis.","volume":"226","author":"Coquette","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"R108-10-20210202","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/00007890-199305000-00036","article-title":". 15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine.","volume":"55","author":"Dumble","year":"1993","journal-title":"Transplantation"},{"key":"R109-10-20210202","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMoa051620","article-title":". Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion.","volume":"353","author":"Fischer","year":"2005","journal-title":"N Engl J Med"},{"key":"R110-10-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.ju.0000129002.42004.4e","article-title":"Group B streptococcal septicemia following intracavernous injection therapy for erectile dysfunction in diabetes.","volume":"172","author":"Nalesnik","year":"2004","journal-title":"J Urol"},{"key":"R111-10-20210202","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00000542-200404000-00040","article-title":"Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin.","volume":"100","author":"Augoustides","year":"2004","journal-title":"Anesthesiology"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e31820e828c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T23:38:39Z","timestamp":1741217919000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201207000-00010"}},"subtitle":["Classification and Therapy With a Focus on Prostaglandin Analogs"],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31820e828c","relation":{},"ISSN":["1075-2765"],"issn-type":[{"type":"print","value":"1075-2765"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}